32 related articles for article (PubMed ID: 14556680)
1.
Bascuas T; Moreno M; Grille S; Chabalgoity JA
Front Immunol; 2018; 9():7. PubMed ID: 29410666
[TBL] [Abstract][Full Text] [Related]
2. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
Milligan MG; Bigger E; Abramson JS; Sohani AR; Zola M; Kayembe MKA; Medhin H; Suneja G; Lockman S; Chabner BA; Dryden-Peterson SL
J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241264
[TBL] [Abstract][Full Text] [Related]
3. Orbital plasmablastic lymphoma with remission following chemotherapy.
Degnan AJ; Levy LM
J Radiol Case Rep; 2011; 5(2):1-7. PubMed ID: 22470775
[TBL] [Abstract][Full Text] [Related]
4. Cerebral HSV-1 Vasculitis as a Fatal Complication of Immunosuppression in Non-Hodgkin´s Lymphoma: A Case Report and Review of the Literature.
Nardone R; Carnicelli L; Brigo F; Pikija S; Hauer L; Sellner J
Pathogens; 2020 Mar; 9(3):. PubMed ID: 32151046
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.
Korashy L; El-Zawahry H; Abdou S; Shahin D; Sherif F; Farrag W; Abdel-Khalik O; Salem H; El-Sebaaie A
Clin Med Insights Oncol; 2012; 6():395-405. PubMed ID: 23239932
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Jones JA; Avritscher EB; Cooksley CD; Michelet M; Bekele BN; Elting LS
Support Care Cancer; 2006 Jun; 14(6):505-15. PubMed ID: 16601950
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Gregory SA; Trümper L
Ann Oncol; 2005 Sep; 16(9):1413-24. PubMed ID: 15932900
[TBL] [Abstract][Full Text] [Related]
8. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
9. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
Jacobson JO; Grossbard M; Shulman LN; Neuberg D
Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
[TBL] [Abstract][Full Text] [Related]
10. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
11. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
12. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
14. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
